MaxCyte Inc logo

MXCT - MaxCyte Inc Share Price

155p 0.0  0.0%

Last Trade - 17/02/20

Sector
Healthcare
Size
Small Cap
Market Cap £79.6m
Enterprise Value £68.2m
Revenue £13.9m
Position in Universe 1041st / 1833
Bullish
Bearish
Unlock MXCT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MXCT Revenue Unlock MXCT Revenue

Net Income

MXCT Net Income Unlock MXCT Revenue

Normalised EPS

MXCT Normalised EPS Unlock MXCT Revenue

PE Ratio Range

MXCT PE Ratio Range Unlock MXCT Revenue

Dividend Yield Range

MXCT Dividend Yield Range Unlock MXCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MXCT EPS Forecasts Unlock MXCT Revenue
Profile Summary

MaxCyte, Inc. focuses on cell-based medicines. The Company's cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company's products include instruments, processing assemblies and insourcing services. Its instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT. The Company's MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System and the MaxCyte VLX Large Scale Transfection System enable the development and production of transfected cells for an array of applications. The Company offers a platform, which enables the engineering of a range of cells, including human primary cells. Its products are used in applications, including drug discovery, protein production and cell therapy. The Company offers messenger ribonucleic acid (mRNA) CAR T-cell based platform for immuno-oncology indications, including solid cancers.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated July 31, 1998
Public Since March 29, 2016
No. of Shareholders: n/a
No. of Employees: 32
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange (AIM)
Shares in Issue 51,357,764
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MXCT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MXCT
Upcoming Events for MXCT
Similar to MXCT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.